Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonyf NVXPAR:MLBON 12 Receivables Turnover is 5.68 as of Dec. 2024. GuruFocus rates XPAR:MLBON with a GF Score™ of 12/100 and a GF Value™ of €8.61 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Bonyf NV ranks better than 51.72% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bonyf NV's Revenue for the
six
months ended in Dec. 2024 was €0.28 Mil. Bonyf NV's average Accounts Receivable for the
six
months ended in Dec. 2024 was €0.05 Mil.
Hence, Bonyf NV's Receivables Turnover for the
six
months ended in Dec. 2024 was 5.68.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Bonyf NV Receivables Turnover Related Terms
Bonyf NV Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Bonyf NV's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonyf NV Receivables Turnover Chart
Bonyf NV Annual Data
Trend
Dec19
Dec20
Dec22
Dec23
Dec24
Receivables Turnover
28.06
19.13
2.10
3.75
5.68
Bonyf NV Semi-Annual Data
Dec19
Dec20
Dec22
Dec23
Dec24
Receivables Turnover
28.06
19.13
2.10
3.75
5.68
XPAR:MLBON vs ISRG, BDX, MDLN: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Bonyf NV's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonyf NV Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonyf NV's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Bonyf NV's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonyf NV (XPAR:MLBON) has a Receivables Turnover of 5.68 as of Dec. 2024. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bonyf NV and its competitors. According to the industry distribution chart, Bonyf NV ranks #392 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 48.3%.
Is Bonyf NV's Receivables Turnover too high?
Bonyf NV's current Receivables Turnover is 5.68. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Bonyf NV's value of 5.68 is 3.1% above this industry median. Based on the distribution chart, Bonyf NV ranks #392 out of 812 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bonyf NV has a GF Score™ of 12/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonyf NV's Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonyf NV ranks #392 out of 812 companies for Receivables Turnover. This puts Bonyf NV in the upper half of its industry. The industry median Receivables Turnover is 5.51. Bonyf NV's value of 5.68 is 3.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonyf NV's current Receivables Turnover of 5.68 is 3.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bonyf NV and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonyf NV's current Receivables Turnover is 5.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonyf NV stock overvalued right now?
Based on GuruFocus' analysis, Bonyf NV (XPAR:MLBON) is currently considered Possible Value Trap. The stock's GF Value™ is €8.61, compared to a current price of €2.48 — trading 71.2% below its estimated fair value. The current Receivables Turnover is 5.68 and 3.1% above the Medical Devices & Instruments industry median of 5.51. Bonyf NV's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Bonyf NV (XPAR:MLBON), the current Receivables Turnover is 5.68 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonyf NV (XPAR:MLBON) Overvalued in 2026?
Based on GuruFocus' analysis, Bonyf NV stock appears to be undervalued.
The current stock price of €2.48 is trading 71.2% below its estimated GF Value™ of €8.61.
GuruFocus considers Bonyf NV to be Possible Value Trap.
Key valuation signals for XPAR:MLBON:
Receivables Turnover: 5.68
GF Value™: €8.61 vs. price of €2.48 (71.2% below fair value)
Industry Position: 3.1% above the Medical Devices & Instruments median (#392 of 812)
No single metric tells the full story. See the XPAR:MLBON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonyf NV specializes in developing, producing and selling cutting-edge oral & dental care products. It is a forward-thinking company committed to revolutionizing oral care through innovation and research.
12GF Score
Get the complete analysis for XPAR:MLBON
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLBON has been successfully added to your 
